Accelerated Aging, HIV Infection, Antiretroviral Therapies

NCT01038999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2012-12-27

No results posted yet for this study

Summary

The main goal is to confirm, among HIV1-infected patients, data from in vitro studies showing that antiretroviral therapies induce an accelerated aging through the same mechanisms than genetic laminopathies or than "physiological " aging, that is through the synthesis and persistence of farnesylated prelamin A. The secondary goal is to measure the impact of HIV infection and of antiretroviral therapies on markers of cell ageing (proteasome, mitochondria, telomere). The perspective is to fix antiretroviral therapy side effects using the same drug combination that will be used in few weeks in Marseille to treat children suffering from progeria

Conditions

  • HIV Infection
  • Aging Accelerated
  • Antiretroviral Therapies

Interventions

BIOLOGICAL

Peripheral blood biological tests

A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.

Sponsors & Collaborators

  • French National Agency for Research on AIDS and Viral Hepatitis

    lead OTHER_GOV

Principal Investigators

  • Isabelle POIZOT-MARTIN · CHU Sainte Marguerite -Marseille

  • Marie-Pierre DROGOUL · CHU Sainte Marguerite -Marseille

  • Olivia FAUCHER · CHU Sainte Marguerite -Marseille

  • Amélie MENARD · CHU Sainte Marguerite -Marseille

  • Joëlle MICALLEF-ROLL · CHU Timone

  • Jacques REYNES · CISIH CHRU Gui de Chauliac- Montpellier

  • Pierre DELLAMONICA · CISIH CHU Nice

  • Pierre CAU · INSERM UMR S910 MARSEILLE

  • Catherine TAMALET · Laboratoire Virologie Marseille

  • Bruno LACARELLE · Unité INSERM U911 Marseille

  • Nicolas LEVY · Laboratoire Génétique Moléculaire Marseille

  • Patrick ROLL · Laboratoire biologie cellulaire Marseille

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-04-30
Completion
2012-03-31

Countries

  • France

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038999 on ClinicalTrials.gov